2015年6月25日，温州医科大学实验医学与生命科学学院的Shouhua Lai (第一作者) & Yunting Guo (第一作者) & Tieli Zhou (通讯作者 音译 周铁丽) & Jiegen Jiang (通讯作者) & Jimin ...

You have full access to this article via your institution. To demonstrate the power of PCR–mediated recombination and provide an example of the general utility of the method, we constructed ...

正在西班牙巴塞罗那召开的2024年欧洲肿瘤内科学会（ESMO）大会上，中山大学肿瘤防治中心徐瑞华教授以口头报告形式公布了一项Ⅰ期临床研究的初步 数据 1 。 该研究评估了新型抗体偶联药物（ADC）SHR-A1904用于Claudin18.2阳性的胃癌 ...

这种GRF-GIF遗传转化系统为高难度、高效率的大豆基因工程提供了一条新路径，未来可能在农业生产中发挥重要作用。随着研究的深入，科学家们有望在大豆及其他作物的改良上取得更多突破，将基因技术的潜能转化为实际的生产力。

This is best exemplified by chimeric antigen receptor (CAR) T-cells. Since first being tested in a patient nearly 15 years ago, six CAR T-cell products have been approved by the US Food and Drug ...

T-cell therapy has increased rapidly, the clinical benefit seen with these products comes at a cost for patients who experience toxicities related to the induction of a powerful immune response. The ...

Cell and gene therapy: Dr. Jeff Hersh examines 25 years of technological advances In general, earlier stage cancers have ...

However, clinical studies of first-generation products targeting B-cell antigens demonstrated limited expansion and in vivo activity. Jensen et al 17 showed that outcomes of 15 CD19- or CD20-specific ...

Chimeric antigen receptor (CAR) T cell therapy is an approach that uses your own immune cells to fight cancer and has shown great promise in treating some types of blood cancers. Our researchers ...

Researchers mined the molecular foundations of cancer and uncovered a new reason chimeric antigen receptor (CAR-T cell therapy) fails in some patients. This discovery has fueled new strategies that ...

Legend Biotech's valuation is conservative, suggesting potential for significant appreciation and growth ahead. Click here to ...